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ABSTRACT 
     Myelin basic protein (MBP) is one of the most important constituents of the CNS myelin sheaths. 
It is supposed that an autoimmune response directed against MBP is crucial in the demyelination 
process in patients with multiple sclerosis. Studies have proved that free anti-MBP level in CSF of 
MS patients is declined when the patient entered into clinical remission. Some researchers evaluate 
the changes in serum or CSF level of this antibody during immunomodulatory therapy; the results are 
different and the relation between the changes in this antibody and response to treatment is poorly 
investigated. The objective of this study was to assess the relation between the changes in serum level 
of anti-MBP and clinical remission in patients during treatment with fingolimod. 37 MS patients that 
were non responder to interferon and glatiramer acetate and were candidates to receive fingolimod 
were nominated for this study.  In this study, the serum level of anti-MBP was evaluated before and 
after 3 and 6 months of therapy and clinical remission was assessed by changes in Expanded 
Disability Status Scale (EDSS) scores. The result of this study showed that MS patients, after 
treatment with interferon, have lower serum anti-MBP level than healthy control group and this 
difference is statistically significant (p =0.03).  The present study demonstrated that the serum anti-
MBP level in MS patient during 6 months of treatment with fingolimod significantly decreased 
(p<0.001). However, there was no significant difference in EDSS of MS patients during 6 months of 
treatment with fingolimod ( p < 0.001).  
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INTRODUCTION 
     Multiple sclerosis (MS) is an inflammatory 
demyelinating disease that is considered as the 
most common disabling neurologic disease in 
young adults [1, 2]. In some ways, each person 
with multiple sclerosis lives with a different 
illness. Although nerve damage is always 
involved, the pattern is unique for each individual 
who has MS. While individual experiences with 
MS vary widely, doctors and researchers have 
identified several major types of MS. The 
categories are important because they help predict 
disease severity and response to treatment [3]. 
With regard to the development and progression of 
the disease, MS is divided into four types – MS;  
Relapsing-Remitting (RR) MS, Primary-
Progressive (PP) MS, Secondary-Progressive (SP) 
MS, Progressive-Relapsing (PR) MS [4]. 
Autoimmune diseases such as MS involve the 
aberrant activation of T cells and/or B cells with 
epitope specificities that are usually excluded from 
the repertoire as the result of self-tolerance which 
is established during early development of the 
immune system [5].Thus, an increase in the 
autoimmune process could be interpreted as 
disease progression in multiple sclerosis [6].  
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Myelin basic protein (MBP) comprises about 30% 
of the central myelin protein and is limited on the 
cytoplasmic side of the myelin sheath [7]. MBP is 
an important autoantigen in multiple sclerosis, 
with the MBP (82–100) area being immune 
dominant for T cells and autoantibodies [8]. 
Because of co-localization of both B and T cell 
responses to the same MBP epitope, it is assumed 
that it plays an important role in the pathogenesis 
of MS [1]. The occurrence of antibodies against 
MBP is demonstrated in early multiple sclerosis 
[9]. B-cells, plasma cells and myelin-specific Abs 
are existent in chronic MS plaques and in areas of 
active myelin’s breakdown in MS patients [10]. It 
has been previously reported that in the majority 
of patients, the MS inflammation had a specific 
autoimmune mechanism directed against MBP, 
specifically its immune dominant epitope P85 
VVHFFKNIVTP96, which is located proximal to 
the tri-Proline sequence (residues 99, 100, 101) 
[11]. Several groups of investigators have 
evaluated the effect of some medicine on anti-
MBP level in serum or CSF of MS patients [12, 
13].  After being treated with presently approved 
immunomodulatory treatments, it takes at least 6–
12 months for the clinical response to appear. 
Apparently, early assessment of response would 
be much better [14]. For this reason, there has 
been much interest in the development of 
applicable biomarkers as a predictor of the 
response to treatment. In this small pilot study,  
the possible relation between the immunological 
and clinical response to fingolimod treatment 
during 6 months interval was examined. 
 
Materials and Methods 
Patient selection 
     All patients who contributed in this project 
were seen at Sina MS research center in Tehran. 
Patients were diagnosed as having clinically 
definite MS by McDonald criteria confirmed by 
MRI of the brain. All patients had received 
interferon or glatiramer acetate for treatment but 
were volunteer for fingolimod at that time. The 
ethics protocol at Sina MS research center was 
followed. All patients were informed of the use of 
the blood that would be put prior to signed 
consent. 
Healthy individuals who matched the participants 
of patient group in sex and age with no diagnosis 
of MS or other chronic diseases and with no MS 
patients in their family were registered in this 
project. Information about age, sex, and the 
clinical assessment of patients is shown in Table 
1. 
 







Age (year) Patient 
3±1.54    7.4±3.9      (8M/29F) 28.3±6.6      37 
Notes: Data are expressed as mean ± SD. EDSS = Expanded Disability Status Scale; M = male; F = female. 
 
Blood sampling 
     Venous blood was collected from MS patients 
into sampling tubes. Samples were centrifuged  
within 60 minutes after sampling at 1000× g for 
15 min. Serum was then  aliquoted and stored at 
−80˚C until assaying. 
 
Anti -MBP determination 
     Serum samples were tested for levels of anti-MBP 
antibodies by enzyme-linked immunosorbent assay. 
For this assay, we purchased Human myelin basic 
protein autoantibody (MBP) ELISA Kit) 
Cat.No：SL1225Hu (from Sun Long Biotech 
Co., LTD. Briefly, this ELISA kit uses sandwich-
ELISA as the method. The Microelisa stripplate 
provided in this kit has been pre-coated with an   
antigen specific to Human myelin basic protein 
autoantibody.  Standard or sample are added to 
the appropriate Micro Elisa strip plate well and 
combined with the specific antigen. 
 After incubation and washing, a Horseradish 
Peroxidase (HRP) conjugated antigen specific for 
Human myelin basic protein autoantibody is 
added to each micro Elisa strip plate well and 
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incubated. Then free components are washed 
away and TMB substrate solution is added to each 
well. Only those well that contain Human myelin 
basic protein autoantibody and HRP conjugated 
Human myelin basic protein autoantibody 
Antibody would appear blue in color and turn 
yellow after the addition of the stop solution. The 
optical density (OD) and concentration was 
measured spectrophotometrically at the 
wavelength of 450 nm. 
Clinical assessments 
     Quantitative neurological assessments and 
EDSS scores were assessed two times: before 
entry and after 6-month interval during treatment. 
An independent Neurologist, experienced in MS 
clinical trials, compiled the EDSS scores.  
Clinical progression was defined as a continuous 
(6 months) increase in EDSS scores of 1 unit if 
the baseline score was <5.5 or of 0.5 units if the 
baseline was 5.5 or higher. 
Statistical analysis 
     The SPSS software (version 20) was used for 
the statistics analysis. Differences in base line 
anti- MBP level between MS patients and healthy 
subjects were tested by T-test. Comparisons 
between values obtained from the same patients 
during 6 months interval during treatment 
(baseline, after3 and 6 months) were performed 
by using the Repeated Measure test. Clinical 
progression was tested by one-sample T- test (all 
values were normally distributed). A p-value 




     In this study, the male to female ratio was 
similar in MS patients and the healthy control, 
and there were no significant difference (𝜒 2) 
regarding sex (p=0.5) and (T-test) age (p=0.75). 
All the patients were treated with beta interferons 
or with glatiramer acetate. During this study, five 
patients, for reasons such as drug side effects or 
non-cooperation were excluded.  
Baseline levels of anti-MBP antibodies 
measured in MS patients vs. the healthy control 
     This study showed that MS patients, after 
treatment with interferon, had lower serum anti-
MBP level (Figure 1) than healthy participants of 
the control group (p=0.03). 
Levels of anti-MBP antibodies measured in the 
MS patients during treatment with fingolimod 
     Anti-MBP autoantibody levels in serum of 
most fingolimod treated patients were 
significantly (p<0.001) suppressed during 3 or 6 
month. Figure 2 shows this suppression among 
these patients separated by sex. 
Analysis of EDSS progressions at 6 months 
     Contingency analysis of the disease 
progression data at 6 months is shown in Table2. 
Patients are categorized in two groups (progressed 
and not progressed).  Clinical progression  
considers sustained (6 months) increase in EDSS 
scores of 1 unit if the baseline score was <5.5 or 
of 0.5 units if the baseline was 5.5 or higher. 
There was not a statistical significant progression 
in the MS patients during 6 months of fingolimod 
treatment (Figure3)
 
 (A)                                  (B)                                 
Figure 1. The Levels of antibodies against MBP A) in MS patient and healthy group B) in two groups separated by sex 
 




Figure 2. Anti-MBP suppression in fingolimod-treated patients 
 
Table 2: Contingency analysis of the disease progression data at 6 months 
All patients n=32 , p<  0.001 
 female male 
Not progressed 24 7 
Progressed 0 1 
Total 24 8 
 
  
Figure3. Estimated Marginal Mean of EDSS before and after treatment 
This figure shows that women patients are more 








     Demyelination in the brain and spinal cord is 
the main feature of the MS lesion. The tissue 
specificity points to an autoimmune response 
directed against the myelin sheath [15]. Several 
studies support the hypothesis that autoimmune 
mechanism plays a dominating role in the 
development of the multiple sclerosis. In the 
central nervous system, myelin basic protein 
(MBP) and proteolipid protein (PLP) are the main 
parts of the myelin protein [16].   MBP, through 
binding to negatively charged lipids on the 
cytosolic surface of oligodendrocyte membranes, 
is responsible for adhesion of these surfaces in the 
multilayered myelin sheath [17].Several 
techniques have been used to search for the 
presence of anti-MBP antigens in MS patients 
[16]. Evidence proposes that an increase in 
concentrations of Abs in CSF of these patients 
correlate with episodes of MS worsening [18]. 
Clinical benefits of IVIG and plasma exchange in 
MS have also implicated humoral mechanisms in 
the disease process [19]. Panitch et al. identified 
MBP autoantibodies in CSF in 81% of MS 
patients [20]. Warren and Catz had detected MBP 
autoantibodies in CSF of 90–95% of their patients 
with active disease and 77.7% of all MS patients 
[21].  
The detection of autoantibodies in serum has been 
less successful. Cruz et al. detected MBP 
autoantibodies in CSF of 32% of their MS 
patients but were unable to detect autoantibodies 
in any of the matched serum samples using an 
immunoblot method. With the ELISA method, 
they detected MBP antibodies in CSF of 44% of 
their patients and 8% of the sera [22]. Based on 
these observations, anti-MBP may be involved in 
the pathogenesis of MS and therefore methods to 
prevent its synthesis and to keep it undetectable in 
the CNS are potentially important [1].  
 In this project, we have focused on the possible 
humoral aspect of immune system by looking for 
circulating antibodies against MBP in serum of 
MS patients. This study aimed at finding if anti-
MBP level in serum of MS patient decreases 
during treatment with fingolimod and if there is 
any relationship between response to treatment 
and decrease in anti-MBP level. The results of 
this study are similar to data from previous long-
term follow-up studies in some interesting ways. 
First, in this study, it was shown that anti-MBP 
autoantibody levels in serum of most fingolimod 
treated patients were suppressed.  Warren and 
Catz find this result in CSF of MS patient during 
treatment with MBP8298 (13). Second, antibody 
suppression was not predictive of clinical benefit. 
There was no significant difference in EDSS of 
MS patient during 6 months treatment with 
fingolimod. During this study, it was found that 
MS patients had lower serum anti-MBP level than 
healthy controls, after treatment with interferon. 
There is a controversy here. Angelucci et al. 
evaluated the effect of interferon-beta (β) therapy 
on anti-myelin antibodies.  They concluded that 
1-year of interferon-β treatment did not induce 
any changes in the levels of anti-MOG and anti-
MBP antibodies. The present study suggested that 
in Iranian MS patient, interferon-beta (β) therapy 
may decrease serum anti-MBP antibodies level. 
These conflicting are: a) Analysis of antibodies 
intensely depends on the detection method used 
and its sensitivity and the conformation status of 
the antigen. For example, in solid-phase assays, 
the antigen is transferred to an artificial surface. 
As a result, protein denaturation may occur, and 
new epitopes not present in the native tertiary 
structure of the folded protein molecule may be 
exposed. b) It is imaginable that one antibody 
against a specific peptide sequence is directly 
concerned with myelin damage while the 
presence of antibodies against other regions of 
myelin protein may signify a secondary 
phenomenon not necessarily related to the 
disease.  
In the other hand, it should also be noted that the 
duration of follow-up in this study was limited to 
6 months. Obviously, follow-up for a long period 
would have allowed for detection of a correlation 
between antibody status and clinical benefit. Also 
a long-term study will be required to reliably 
define the role of HLA as markers of treatment 
response to fingolimod.  
CONCLUSION 
     The results of this study show that there is 
anti-MBP in serum of healthy people, without any 
symptom of MS disease. As a result, the presence 
of antibodies against myelin antigens couldn’t be 
the mere cause of MS and other conditions are 
needed for symptoms outbreak. However, 
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following the healthy people who have high 
serum anti-MBP level is effective for better 
understanding of this antibody’s role in MS 
pathogenesis and may represents clear results in 
connection with this antibody and incidence of 
MS . Given the lower level of anti-MBP in MS 
patients than in healthy subjects after treatment 
with interferon, it is suggested that in Iranian MS 
patients, interferons may reduce this antibody’s 
level. The baseline level of anti-MBP in one 
patient who has a significant increase in the EDSS 
level during these 6 months was higher than other 
patients. Perhaps Baseline blood serum anti-MBP 
levels can be used to identify populations of MS 
patients in which treatment with fingolimod is 
associated with a significant remission after 6 
months of treatment with fingolimod.   
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